Iconovo AB (publ) (STO:ICO)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.120
-0.020 (-1.75%)
At close: Feb 10, 2026
Market Cap83.78M -14.0%
Revenue (ttm)16.79M -32.8%
Net Income-41.23M
EPS-1.41
Shares Out74.80M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume7,994
Average Volume131,723
Open1.130
Previous Close1.140
Day's Range1.100 - 1.140
52-Week Range1.045 - 4.540
Beta0.44
RSI44.59
Earnings DateFeb 27, 2026

About Iconovo AB

Iconovo AB (publ) develops inhaled medicinal products in Sweden. The company offers ICOres, a multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has a collaboration agreement with Lonza to develop spray-dried formulations of an intranasal biologic drug; and agreement with Kiox Pharma to develop an inhalable treatment for ... [Read more]

Sector Healthcare
Founded 2013
Employees 19
Stock Exchange Nasdaq Stockholm
Ticker Symbol ICO
Full Company Profile

Financial Performance

In 2024, Iconovo AB's revenue was 24.00 million, a decrease of -14.62% compared to the previous year's 28.11 million. Losses were -41.14 million, -10.36% less than in 2023.

Financial Statements